TWST
Fiscal year ends September Quarters are offset from the calendar — Q1 is Oct–Dec

Twist Bioscience Corporation is a synthetic biology company that develops a silicon-based DNA synthesis platform to manufacture synthetic DNA, RNA, and proteins. The company’s core technology writes oligonucleotides on silicon chips to enable high-throughput, scalable production of synthetic genes, gene fragments, and next-generation sequencing (NGS) tools. Its product portfolio includes synthetic biology tools for drug discovery, disease detection, and enzyme engineering, as well as NGS target enrichment panels, library preparation kits, and variant libraries. Twist Bioscience also provides biopharma services for antibody discovery, optimization, and characterization. The company serves a global customer base across healthcare, chemicals and materials, food and agriculture, and academic research sectors, supporting applications in therapeutics, diagnostics, industrial materials, and crop improvement.

Summarised from the company's own disclosures, fiscal year ended Nov 2025

Industry Biotechnology Homepage twistbioscience.com
Sector Healthcare IR page investors.twistbioscience.com
Tags
dna synthesis, synthetic biology, next-generation sequencing, antibody discovery, drug discovery, gene editing, target enrichment, library preparation, variant libraries, oligonucleotides, biopharma services, industrial biotechnology, Twist TrueAmp Library Preparation Kit, cfDNA Library Prep Kit, EM-seq v2 Methylation Detection System, cfDNA Pan-Cancer Reference Standard v2, Respiratory Virus Controls, Combinatorial Variant Library, Site Saturation Libraries, Enzyme Screening kits, Fast Hybridization Solution, Standard Hybridization Solution, PCR-Free WGS Library Prep Kit, SARS-CoV-2 Research Panel, Comprehensive Viral Research Panel, Respiratory Virus Research Panel, MRD Express, Sequence Design Workbench, Manufacturability Analyzer, Twist Oligo Pools
Press page —

Metrics

Valuation  
Market cap $ 7.031B
Market cap (USD) $ 7.031B
P/E -49.85
PEG —
P/BV 7.92
P/S 15.30
P/OCF -169.71
P/FCF -78.99
Dividend yield —
Turnover / mcap —
Returns  
ROE -19.1%
ROI -29.6%
ROIC -23.7%
Profit margin -28.3%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 19
Quality score -33.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 459.433M 376.572M 312.974M 245.109M 203.565M 132.333M 90.1M 54.385M 25.427M —
Net profit -130.202M -77.67M -208.726M -204.618M -217.863M -152.098M -139.931M -107.669M -71.236M -59.31M
Free cash flow -89.014M -75.632M -69.17M -170.253M -226.242M -139.305M -152.123M -102.694M -69.852M -57.895M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 193.24 28.14 45.18 20.26 35.24 106.97 75.97 23.88 — —
Price performance 12m 5.87 -0.38 1.23 -0.43 -0.67 0.41 2.18 — — —

Filed figures

Figure Sep 2017 Sep 2018 Sep 2019 Sep 2020 Sep 2021 Sep 2022 Sep 2023 Sep 2024 Sep 2025 Sep 2026
Balance sheet detail
Trade receivables (USD) 2.35M 5.42M 12.1M 26.4M 28.5M 40.3M 44.1M 34.9M 57M 70.2M
↳ YoY growth +131.0% +123.4% +117.9% +8.2% +41.1% +9.4% -20.8% +63.4% +23.1%
↳ 5y CAGR +76.6% +52.1% +23.6% +16.7% +19.7%
Borrowings, current (USD) 0.00 2.5M 3.33M 3.33M 1.55M 0.00 — — — —
Borrowings, non-current (USD) 9.15M 7.22M 4.4M 1.4M — — — — — —
Lease liabilities (USD) — — — 31.2M 61.4M 94.9M 94.1M 85M 75.6M 95M
Cash and deposits (USD) 31.2M 80.8M 46.7M 93.7M 466M 379M 286M 226M 183M 534M
Intangible assets (USD) 920,000 712,000 508,000 307,000 18.3M 59.7M 54.5M 14.5M 13.4M 34.2M
Right-of-use assets (USD) — — — 33.7M 61.6M 74.9M 71.5M 58.8M 49.4M 69.3M
Net debt (borrowings + leases - cash) (USD) -22.1M -71M -39M -57.7M -403M -284M — — — —
Cash flow detail
Operating cash flow (USD) -51.3M -66.2M -87.9M -142M -112M -124M -142M -64.1M -47.6M -41.4M
Purchases of property, plant and equipment (USD) 6.59M 3.69M -14.8M -9.87M -27.1M -102M -27.8M -5.08M -28M -47.6M
Purchases of intangible assets (USD) — — — — -18.4M — — 0.00 0.00 -6.95M
Change in receivables (cash effect) (USD) 1.62M 3.07M -6.69M -14.3M -2.2M -9.62M -4.32M 8.44M -22.4M -13.8M
Change in inventories (cash effect) (USD) 599,000 4.2M -1.3M -4.96M -19.5M -7.54M 7.24M 7.99M -4.23M -18.1M
Change in payables (cash effect) (USD) 560,000 3.76M 3.28M -5.51M 8.54M 7.38M -2.51M -11.8M 9.33M 13.9M
Interest paid (cash effect) (USD) -702,000 -751,000 -779,000 -438,000 -167,000 -9,000 0.00 0.00 — —
Income taxes paid (cash effect) (USD) -6,000 -179,000 -291,000 -172,000 -101,000 -246,000 -420,000 -344,000 -683,000 -310,000
Share-based compensation (USD) 1.89M 2.96M 11.2M 17.1M 37M 79.7M 30.3M 50.9M 64.5M 69.9M
Operating cash flow before change in receivables (USD) -52.9M -69.2M -81.3M -128M -110M -115M -138M -72.5M -25.2M -27.6M
Free cash flow (OCF - PPE - intangibles) (USD) -57.9M -69.9M -103M -152M -158M -226M -170M -69.2M -75.6M -96M
Income detail
Research and development expense (USD) 19.2M 20.3M 35.7M 43M 69.1M 120M 107M 90.9M 80.3M 71.8M
↳ 5y CAGR +30.5% +44.4% +39.3% +20.6% +13.3% +0.8%
Total comprehensive income (USD) -59.3M -71.2M -108M -140M -152M -220M -204M -208M -77.8M -130M
Comprehensive income to owners (USD) -59.3M -71.2M -108M -140M -152M -220M -204M -208M -77.8M -130M
Provision for credit losses (USD) — — — 0.00 40,000 -11,000 — — — —
Credit cost ratio (credit losses / average receivables) (%) — — — 0.0% 0.1% 0.0% — — — —
Reported Dec 20, 2018 Dec 20, 2018 Dec 13, 2019 Nov 28, 2022 Nov 23, 2021 Nov 28, 2022 Nov 21, 2023 Nov 16, 2026 Nov 16, 2026 Nov 16, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

— Record revenue of $459.4 million in Fiscal 2026; Increase of 22% over $376.6 million in Fiscal 2025 —

— Record revenue of $126.6 million in 4QFY26; Increase of approximately 28% over $99.0 million in 4QFY25; 15th consecutive quarter of sequential growth —

— Gross margin of 52.4% in fiscal 2026, Improvement of 1.7 margin points versus 50.7% in fiscal 2025 —

— Fiscal 2027 revenue guidance of $550M-$560M, growth of 21% year over year at the midpoint —

— First quarter fiscal 2027 revenue guidance of $130M to $132M, growth of 26% year over year at the midpoint —

SOUTH SAN FRANCISCO, Calif. -- (November 12, 2026) — Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today reported financial results and business highlights for the fourth quarter and full year fiscal 2026 ended September 30, 2026.

“Fiscal 2026 demonstrated what Twist can deliver: strong top line revenue growth, expanded gross margin and positive adjusted EBITDA in the fourth quarter, all while continuing to broaden our capabilities and strengthen our balance sheet," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

Skip to main navigation

IR banner image

print-logo

Investor Relations

Investors

Press Release Details

Notice of Proposed Derivative Settlement: Twist Bioscience Corporation

Nov 03, 2026

PDF Version

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 3, 2026-- Twist Bioscience Corporation (NASDAQ: TWST):

UNITED STATES DISTRICT COURT****DISTRICT OF DELAWARE

| IN RE TWIST BIOSCIENCE CORPORATION DERIVATIVE LITIGATION | Lead Case No. 1:23-cv-01048-MN |

SUMMARY NOTICE OF PROPOSED SETTLEMENT OF DERIVATIVE ACTION

TO: ALL CURRENT RECORD HOLDERS AND BENEFICIAL OWNERS OF TWIST BIOSCIENCE CORPORATION (“TWIST” OR THE “COMPANY”) COMMON STOCK AS OF OCTOBER 15, 2026 (THE “RECORD DATE”).

IF YOU WERE A RECORD OR BENEFICIAL OWNER OF TWIST COMMON STOCK AS OF THE RECORD DATE, PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY AS YOUR RIGHTS MAY BE AFFECTED BY PROCEEDINGS IN****THE ABOVE-REFERENCED LITIGATION.

PLEASE TAKE NOTICE that the above-captioned consolidated derivative action is being settled on the terms set forth in a Stipulation and Agreement of Settlement dated October 15, 2026 (the “Stipulation”),1 subject to the approval of the United States District Court for the District of Delaware (the “Court”) pursuant to Rule 23.1 of the Federal Rules of Civil Procedure. Under the terms of the Stipulation, as part of the proposed Settlement, and in consideration of the associated releases set forth herein, Defendants shall cause the Board, within forty-five (45) days after the Court enters an Order granting final approval of the Settlement, to adopt, implement, and maintain the corporate governance reforms set forth in Exhibit A to the Stipulation, consistent with the terms and timing set forth therein (the “Reforms”). The Reforms, which are detailed more fully in the Stipulation and Long Form Notice, are intended to address the claims asserted in the Derivative Action.

| 1 | Capitalized terms herein not otherwise defined are defined in the Stipulation. This Notice should be read in conjunction with, and is qualified in its entirety by reference to, the Stipulation and its Exhibits, which have been filed with the U.S. District Court for the District of Delaware. |

The Parties agree that: (1) the Settlement confers a substantial benefit upon Twist and its shareholders; (2) the Settlement, and each of its terms, is in all respects fair, adequate, reasonable, and in the best interests of Twist and its shareholders; and (3) Plaintiffs’ Counsel shall be paid reasonable attorneys’ fees and reimbursement of expenses, inclusive of Service Awards for the Plaintiffs, subject to the approval of the Court.

On January 22, 2027, at 10:00 a.m., the Court will hold the Settlement Hearing in Courtroom 4A at the United States District Court for the District of Delaware, 844 N. King Street, Wilmington, Delaware 19801-3555. At the Settlement Hearing, the Court will consider whether the Settlement is fair, reasonable, and adequate and thus should be finally approved and whether the above-captioned consolidated derivative action should be dismissed with prejudice pursuant to the Stipulation. The Court also will rule upon Plaintiffs’ Counsel’s request for approval of the agreed-to attorneys’ fees and reimbursement of expenses and Plaintiffs’ Service Awards.

Any Current Twist Stockholder may, but is not required to, appear at the Settlement Hearing. If you want to be heard at the Settlement Hearing in opposition to the Settlement, Plaintiffs’ Counsel’s request for approval of attorneys’ fees and reimbursement of expenses, or the Service Awards, then you must first comply with the following procedures for objecting.

Any objections to the proposed Settlement or Plaintiffs’ Counsel’s applications for the Fee and Expense Amount of $1,000,000, to be paid by the Individual Defendants’ Insurers, and reasonable Service Awards of up to $2,000 for each of the two Plaintiffs to be paid from the Fee and Expense Amount, must be presented in writing and must contain the following information:

  • Notice of intent to appear at the Settlement Hearing;

  • Your name, legal address, and telephone number;

  • Proof of being a Current Twist Stockholder as of the Record Date and representation that you will continue to own Twist common stock as of the date of the Settlement Hearing;

  • The date(s) which you acquired your Twist shares and the number of Twist shares held;

  • A detailed statement of your specific position with respect to the matters to be heard at the Settlement Hearing, including a statement of each objection being made; and

  • The grounds for each objection or the reasons for your desire to appear and be heard.

Any counsel retained by a putative objector for the purpose of asserting an objection must make a notice of appearance on the Court at least fourteen (14) days before the Settlement Hearing. The Court may not consider any objection that does not substantially comply with these requirements.

Any written objections must be filed with the Court and sent by hand or by first class mail, postage pre-paid to Plaintiffs’ Counsel and Defendants’ Counsel no later than fourteen (14) days prior to the Settlement Hearing at the following address:

| Plaintiffs’ Counsel: Herbert W. Mondros RIGRODSKY LAW, P.A. 1007 North Orange Street, Suite 453 Wilmington, DE 19801 Telephone: (302) 295-5310 Email: [email protected] Defendants’ Counsel: James N. Kramer ORRICK, HERRINGTON & SUTCLIFFE LLP The Orrick Building 405 Howard Street San Francisco, California 94105-2625 Telephone: (415) 773-5700 Email: [email protected] | Clerk of the Court: United States District Court District of Delaware 844 North King Street, Unit 18 Wilmington, DE 19801-3570 Telephone: (302) 573-6170 |

The Court may not consider any objection that is not timely filed with the Court and delivered to Plaintiffs’ Counsel and Defendants’ Counsel.

Any person or entity who fails to object or otherwise requests to be heard in the manner prescribed above will be deemed to have waived the right to object to any aspect of the Settlement, will be deemed to have waived any request to be heard (including the right to appeal), and will be forever barred from raising such objection or request to be heard in this or any other action or proceeding, but shall otherwise be bound by the Judgment to be entered and the releases to be given.

This Notice summarizes the Parties’ Stipulation. It is not a complete statement of the events of the Derivative Action or the Stipulation. You may inspect the Stipulation and other papers at https://investors.twistbioscience.com/.

PLEASE DO NOT CALL, WRITE, OR OTHERWISE DIRECT QUESTIONS TO EITHER THE COURT OR THE CLERK’S OFFICE. Any questions you have about matters in this Notice should be directed by telephone or in writing to Plaintiffs’ Counsel and Defendants’ Counsel at the addresses set forth above.

| Dated: October 20, 2026 | BY ORDER OF THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE |

View source version on businesswire.com: https://www.businesswire.com/news/home/20261103793144/en/

For Investors: Angela Bitting SVP, Corporate Affairs 925-202-6211 [email protected]

For Media: Amanda Houlihan Communications Manager 774-265-5334 [email protected]

Source: Twist Bioscience Corporation

Quick Links

Twist Bioscience Logo

Twist Bioscience HQ 681 Gateway Blvd South San Francisco, CA 94080

The figures contained in the analyst consensus tables are a simple arithmetic average of the most recent forecasts that have been provided to Twist. The figures do not give greater weight to more recent forecasts or to the forecasts of any individual analyst.

Moreover, the data has not been adjusted to exclude any submission.

The information is provided purely for convenience to users of our website, for information purposes only. This information is, by definition, forward-looking and is therefore subject to various risks and uncertainties which are subject to change at any time and may materially affect actual results or performance.

The consensus data is based on the analysts' opinions, forecasts, estimates, projections and predictions regarding Twist's performance.

It does not represent Twist's own views on its performance nor does Twist endorse or concur with any of such analysts’ opinions, estimates, forecasts or recommendations. Twist has not verified any of the information it has received and none of Twist, its affiliates or their respective directors, officers and employees make any representation or warranty, express or implied, as to, or accept any responsibility for, the accuracy or completeness of the consensus information. Twist does not assume any responsibility to update, revise or supplement such information.

The consensus data was last updated on November 20, 2025.

Continue

Skip to main navigation

IR banner image

print-logo

Investor Relations

Investors

Press Release Details

Twist Bioscience Launches MRD Express with Rapid Turnaround Time

Oct 29, 2026

PDF Version

Turnaround time starting within one day

Twist panel enables researchers to combine the sensitivity of tumor-informed MRD detection with the speed and simplicity of tumor-naïve MRD detection when developing their tests

Twist capacity enables high-throughput production of custom MRD Express panels of up to 10,000 probes at the speed and scale needed by researchers

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 29, 2026-- Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched Twist MRD Express, custom panels manufactured at scale with a rapid turnaround time starting within one day. Twist MRD Express custom panels enable cancer researchers to investigate tumor-associated genomic variants and support studies in oncology research, biomarker discovery and assay development.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029639258/en/

Twist MRD Express custom panels

Twist MRD Express custom panels

Molecular residual disease (MRD) is the presence of a small amount of tumor-derived molecules, including genetic material that remain after cancer treatment. Researchers take one of two approaches when developing molecular residual disease (MRD) tests: tumor-informed, which incorporates a person’s individual tumor variants in a personalized panel to identify recurrence, or tumor-naïve, which uses common biomarkers across a particular cancer indication to test multiple patients for these shared biomarkers. Tumor-informed MRD testing has higher sensitivity but is traditionally slower to develop due to personalization. With Twist MRD Express, cancer researchers can access personalized tumor-informed panels manufactured at scale and delivered on tumor-naïve timelines.

“To understand how cancer is responding at the molecular level, researchers need workflows that move as quickly as their questions demand,” said Emily M. Leproust, CEO and co-founder of Twist Bioscience. “With personalized Twist MRD Express panels we are eliminating the tradeoff researchers need to make between sensitivity and speed, enabled by enhancements to our manufacturing and automation processes within our existing high-throughput environment. Importantly, as MRD providers scale, their supply chains need to keep pace. Our platform is built to support that growth, giving customers confidence to plan beyond today’s testing volumes.”

About Twist MRD Express

The Twist MRD Express panel enables cancer researchers to pursue personalized, high specificity tumor-informed MRD testing without compromising on speed. The MRD Express panel can include up to 10,000 probes with industry-leading oligo quality and high uniformity. Panels incorporate modified bases, including locked nucleic acids (LNA), which can further improve sequencing sensitivity. With bioinformatics panel design support, ecommerce and touchless API ordering for the Twist MRD Express panel, Twist can enable customers’ workflows at any stage. The Twist MRD Express panel is the latest evolution in Twist’s robust offering of tools that enable the liquid biopsy and MRD research communities, including Twist’s cfDNA Library Preparation Kit with TrueAmp™ Polymerase Mix and Twist cfDNA Pan-Cancer Reference Standard v2.

Twist’s high-throughput silicon-based DNA synthesis platform is designed to help MRD providers build a supply chain that scales with their ambitions. By producing large numbers of customized probes in parallel, Twist can support growing demand as customers expand testing volumes and develop more comprehensive panels.

About Twist Bioscience Corporation

At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets.

We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal – more experiments, more iterations, more chances for remarkable discoveries.

Together, we stand with customers in the relentless pursuit of progress, backed by enterprise reliability, to shape a healthier and more sustainable future for all. For more information about our products and services, please visit www.twistbioscience.com.

Follow us on LinkedIn | X | YouTube | Instagram | Bluesky

Twist Bioscience Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements regarding the expected performance, benefits and turnaround times of Twist MRD Express, and Twist’s capacity to meet future demand. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; the ability to integrate and leverage artificial intelligence and machine learning technologies to improve operational efficiency, product development, and customer solutions; the ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist’s costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; the ability to maintain and enforce intellectual property protection; uncertainty as to economic and market conditions and the impact of adverse economic conditions; and the ability to obtain financing when necessary. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist’s business in general, see Twist’s risk factors set forth in Twist’s Annual Report on Form 10-K for the year ended September 30, 2025 filed with the Securities and Exchange Commission (SEC) on November 17, 2025 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261029639258/en/

**FOR TWIST:**For Investors: Angela Bitting SVP, Corporate Affairs 925-202-6211 [email protected]

For Media: Amanda Houlihan Communications Manager 774-265-5334 [email protected]

Source: Twist Bioscience Corporation

Quick Links

Twist Bioscience Logo

Twist Bioscience HQ 681 Gateway Blvd South San Francisco, CA 94080

The figures contained in the analyst consensus tables are a simple arithmetic average of the most recent forecasts that have been provided to Twist. The figures do not give greater weight to more recent forecasts or to the forecasts of any individual analyst.

Moreover, the data has not been adjusted to exclude any submission.

The information is provided purely for convenience to users of our website, for information purposes only. This information is, by definition, forward-looking and is therefore subject to various risks and uncertainties which are subject to change at any time and may materially affect actual results or performance.

The consensus data is based on the analysts' opinions, forecasts, estimates, projections and predictions regarding Twist's performance.

It does not represent Twist's own views on its performance nor does Twist endorse or concur with any of such analysts’ opinions, estimates, forecasts or recommendations. Twist has not verified any of the information it has received and none of Twist, its affiliates or their respective directors, officers and employees make any representation or warranty, express or implied, as to, or accept any responsibility for, the accuracy or completeness of the consensus information. Twist does not assume any responsibility to update, revise or supplement such information.

The consensus data was last updated on November 20, 2025.

Continue

Prompts

Twist Bioscience Corporation (ticker TWST), listed in United States.

ETFs Holding Twist Bioscience Corporation

ETF Weight in ETF Shares Market value As of
ARKG 8.50% 1,381,558 $ 154.734M Nov 18, 2026
FRTY 4.79% 71,651 $ 7.371M Jun 30, 2026
ARKK 3.13% 3,550,460 $ 397.652M Nov 18, 2026
HELX 2.85% 7,736 $ 795.88K Jun 30, 2026
LFSC 2.03% 18,448 $ 2.564M Aug 31, 2026
TSME 1.38% 140,652 $ 14.47M Jun 30, 2026
FMED 1.35% 5,000 $ 695K Aug 31, 2026
MMSC 0.92% 4,379 $ 459.97K Nov 16, 2026
SCDS 0.70% 572 $ 64.064K Nov 17, 2026
JTEK 0.67% 237,199 $ 26.566M Nov 17, 2026
TTEQ 0.62% 27,626 $ 2.902M Nov 17, 2026
JSML 0.61% 24,247 $ 2.22M Jul 31, 2026
ESSC 0.45% 1,785 $ 163.417K Jul 31, 2026
BAI 0.44% 477,783 $ 50.186M Nov 16, 2026
FSEG 0.40% 220 $ 22.634K Jun 30, 2026
FSCC 0.38% 9,979 $ 1.387M Aug 31, 2026
FTKI 0.32% 766 $ 80.461K Nov 16, 2026
AFSM 0.27% 3,804 $ 399.572K Nov 16, 2026
FESM 0.26% 147,252 $ 15.149M Jun 30, 2026
FFSM 0.24% 39,543 $ 3.62M Jul 31, 2026
RESM 0.19% 69 $ 7,098.72 Jun 30, 2026
AFMC 0.18% 4,534 $ 476.251K Nov 16, 2026
WCEO 0.17% 188 $ 17.211K Jul 31, 2026
VFMO 0.15% 21,044 $ 2.925M Aug 31, 2026
ORR short -0.13% -4,272 $ -480K Nov 18, 2026
MSSM 0.06% 3,049 $ 423.811K Aug 31, 2026
DFAS 0.04% 118,391 $ 13.523M Nov 12, 2026
DFAC 0.01% 60,037 $ 6.857M Nov 12, 2026
AVSU 0.00% 8 $ 840.32 Nov 16, 2026